Alteogen
Update in progress196170.KQ (KOSDAQ)
- Company RatingNeutralCompany RatingCombines sentiment and sustainability signals into an overall assessment of the company.Great · Good · Neutral · At Risk · Poor
- SectorHealthcare
- IndustryBiotechnology
ALTEOGEN Inc. is a biopharma company developing long-acting biobetters, antibody-drug conjugates, and antibody biosimilars. Its pipeline includes ALT-P1 (long-acting growth hormone, Phase IIa), ALT-Q2 (long-acting factor VII for hemophilia), ALT-P7 (targeted cancer drug, Phase I), ALT-Q5 (ADC for ovarian cancer), and ALT-LS2 (subcutaneous trastuzumab). It collaborates with Kissei (ALT-L9 Eylea biosimilar), Cristalia (ALT-L2 trastuzumab biosimilar), and Biogen (SC biologics ALT-B4). Founded 2008 in Daejeon, Korea.
Company score
- Sentiment
- 0.46
- SentimentMeasures the overall tone of recent coverage and discussion about the company.−10 negative · 0 neutral · +10 positive
- Environment
- 0.00
- EnvironmentAssesses the company’s environmental impact, risks, and sustainability practices.−10 negative · 0 neutral · +10 positive
- Social
- 0.17
- Governance
- 0.10
- GovernanceAssesses leadership, accountability, transparency, and business ethics.−10 negative · 0 neutral · +10 positive
- Sustainability
- 0.07
- SustainabilityCombines environmental, social, and governance signals into an overall sustainability score.−10 negative · 0 neutral · +10 positive
- Impact Score
- 0.26
- Impact ScoreCombines sentiment and sustainability performance into an assessment of the company’s overall impact.−10 negative · 0 neutral · +10 positive
Sort by
Order by
Timeframe
No news articles are available for this company yet.
Unable to load company news.
Loading more news
You're all caught up!